Back as CEO
Swedish Oncopeptides has had a new CEO since mid-November. Jakob Lindberg has taken over the position from Marty J. Duvall again. He has left the company.
ADVERTISEMENT
About Michael Kuhrt
This author has not written his bio yet.
But we are proud to say that Michael Kuhrt contributed 541 entries already.
Entries by Michael Kuhrt
Building on the advances made during the pandemic
The pharmaceutical industry has made significant advances in collaboration over the past two years, and I have seen many examples amongst Pistoia Alliance members of the power of cooperative working. It is imperative that the industry continues to build on these successes.
Vaccines burst 2021 biotech bubble
Despite a couple of notable ‘firsts’ for European public biotech financing, biotech’s COVID-19 bubble may be about to burst. Virus fears pushed both private and public investors toward biotech, but vaccination successes have changed the sentiment. Now, it seems there are simply too many biotech companies, especially in Europe.
Immunovia in search of a new CEO
Lund-based Immunovia will need a new CEO, because Patrik Dahlen wants to leave the diagnostics company for personal reasons.
Genoskin appointed CSO
Dr Nicolas Gaudenzio has been started at the beginning of November as Chief Scientific Officer of Genoskin.
From interim to permanent
Lotta Ferm, interim CFO of Immunicum AB, was now named as Chief Financial Officer.
BIAL with new R&D General Manager
BIAL, a public limited company under Portuguese law with head office in Coronado, Portugal, appointed Joerg Holenz as R&D General Manager and as a member of the Board of Directors.
Mogrify strengthens leadership team
Cambridge-based Mogrify Limited announced the appointment of Tom Graney CFA as Non-Executive Director, Audit Chair and Capital Markets Advisor.
New CSO for Cellbox Solutions
Since October, Dr. Gisèle Deblandre has strengthened the team of Cellbox Solutions GmbH in Norderstedt near Hamburg as Chief Scientific Officer.
Supporting ulta-rare diseases
Medicines for rare and paediatric diseases have been successfully enabled through the EU’s incentives framework. The number of medicines in development has risen significantly since the introduction of the legislation (3,678 applications for orphan designation by end 2020).